Skip to content
Bending the Curve Trial by Trial
?

Back to Gastric and gastro-oesophageal junction cancer

References: Gastric and gastro-oesophageal junction cancer

93 sources cited on this page. Links open the primary source.

  1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273-5. PubMed
    CiteLoading…
  2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311-5. PubMedDOI
    CiteLoading…
  3. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust. 1985;142(8):436-9. PubMedDOI
    CiteLoading…
  4. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325(16):1127-31. PubMedDOI
    CiteLoading…
  5. International Agency for Research on Cancer. Infection with Helicobacter pylori (Group 1). IARC Summaries & Evaluations, Volume 61 (1994), p. 177, section 5 (Summary of Data Reported and Evaluation). Online text at inchem.org; accessed 20 October 2026. Source
  6. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3(4):219-225. PubMedDOI
    CiteLoading…
  7. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-30. PubMedDOI
    CiteLoading…
  8. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784-9. PubMedDOI
    CiteLoading…
  9. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291(2):187-94. PubMedDOI
    CiteLoading…
  10. The Nobel Foundation. The Nobel Prize in Physiology or Medicine 2005 (NobelPrize.org API record: awarded 2005-10-03, each laureate 1/2; motivation text). Accessed 20 October 2026. Source
  11. The Nobel Foundation. Barry J. Marshall (laureate record 789; birth date and Nobel-listed affiliations). NobelPrize.org API; accessed 20 October 2026. Source
  12. The Nobel Foundation. J. Robin Warren (laureate record 790; birth and death dates). NobelPrize.org API; accessed 20 October 2026. Source
  13. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20. PubMedDOI
    CiteLoading…
  14. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-7. PubMedDOI
    CiteLoading…
  15. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903-9. PubMedDOI
    CiteLoading…
  16. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810-20. PubMedDOI
    CiteLoading…
  17. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46. PubMedDOI
    CiteLoading…
  18. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372(9636):392-7. PubMedDOI
    CiteLoading…
  19. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666-73. PubMedDOI
    CiteLoading…
  20. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. PubMedDOI
    CiteLoading…
  21. European Medicines Agency. Herceptin: EPAR, procedural steps taken and scientific information after the authorisation (archive version). Variation II/0047, extension of indication to HER2-positive metastatic gastric or gastro-oesophageal junction adenocarcinoma. Source
  22. US Food and Drug Administration. Supplement approval letter, Herceptin (trastuzumab), BLA 103792/5250, Genentech; letter dated 20 October 2010. Source
  23. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387-93. PubMedDOI
    CiteLoading…
  24. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315-21. PubMedDOI
    CiteLoading…
  25. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268-73. PubMedDOI
    CiteLoading…
  26. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327-33. PubMedDOI
    CiteLoading…
  27. European Medicines Agency. Cyramza (ramucirumab): European public assessment report, product page and medicine overview; marketing authorisation issued 19/12/2014. Source
  28. US Food and Drug Administration. BLA approval letter, Cyramza (ramucirumab), BLA 125477, Eli Lilly and Company; e-signed 21 April 2014. Source
  29. US Food and Drug Administration. Supplement approval letter, Cyramza (ramucirumab), BLA 125477/S-2, Eli Lilly and Company; e-signed 5 November 2014. Source
  30. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31-39. PubMedDOI
    CiteLoading…
  31. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389-96. PubMedDOI
    CiteLoading…
  32. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-35. PubMedDOI
    CiteLoading…
  33. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697-1708. PubMedDOI
    CiteLoading…
  34. US Food and Drug Administration. Accelerated approval letter, Keytruda (pembrolizumab), BLA 125514/S-24, Merck Sharp & Dohme; e-signed 22 September 2017. Source
  35. Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616-628. PubMedDOI
    CiteLoading…
  36. Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, et al. Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med. 2018;378(12):1085-1095. PubMedDOI
    CiteLoading…
  37. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013. PubMedDOI
    CiteLoading…
  38. Gastrointestinal Endoscopy Group of Japan Clinical Oncology Group (JCOG-GIESG), Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2018;21(1):114-123. PubMedDOI
    CiteLoading…
  39. Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123-133. PubMedDOI
    CiteLoading…
  40. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957. PubMedDOI
    CiteLoading…
  41. Choi IJ, Kim CG, Lee JY, Kim YI, Kook MC, Park B, et al. Family History of Gastric Cancer and Helicobacter pylori Treatment. N Engl J Med. 2020;382(5):427-436. PubMedDOI
    CiteLoading…
  42. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571-1580. PubMedDOI
    CiteLoading…
  43. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-2430. PubMedDOI
    CiteLoading…
  44. Chiang TH, Chang WJ, Chen SL, Yen AM, Fann JC, Chiu SY, et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243-250. PubMedDOI
    CiteLoading…
  45. de Steur WO, van Amelsfoort RM, Hartgrink HH, Putter H, Meershoek-Klein Kranenbarg E, van Grieken NCT, et al. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Ann Oncol. 2021;32(3):360-367. PubMedDOI
    CiteLoading…
  46. European Medicines Agency. Opdivo: EPAR, procedural steps taken and scientific information after the authorisation (archive version). Variation II/0096, extension of indication, first-line HER2-negative gastric, GEJ or oesophageal adenocarcinoma with PD-L1 CPS 5 or more. Source
  47. US Food and Drug Administration. Supplement approval letter, Enhertu, BLA 761139/S-011, Daiichi Sankyo; e-signed 15 January 2021. Source
  48. US Food and Drug Administration. Accelerated approval letter, Keytruda (pembrolizumab), BLA 125514/S-097, Merck Sharp & Dohme; e-signed 5 May 2021. Source
  49. US Food and Drug Administration. Supplement approval letter, Opdivo (nivolumab), BLA 125554/S-091, Bristol Myers Squibb; e-signed 16 April 2021. Source
  50. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40. PubMedDOI
    CiteLoading…
  51. Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727-730. PubMedDOI
    CiteLoading…
  52. Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, et al. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021;39(9):966-977. PubMedDOI
    CiteLoading…
  53. European Medicines Agency. Enhertu: EPAR, procedural steps taken and scientific information after the authorisation (archive version). Variation II/0012, extension of indication to HER2-positive gastric or GEJ adenocarcinoma after a prior trastuzumab-based regimen. Source
  54. US Food and Drug Administration. Supplement approval / release from postmarketing requirement letter, Keytruda (pembrolizumab), BLA 125514/S-125, Merck Sharp & Dohme; e-signed 4 February 2022. Source
  55. Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234-247. PubMedDOI
    CiteLoading…
  56. European Medicines Agency. Keytruda: EPAR, procedural steps taken and scientific information after the authorisation (archive version). Variation II/0133 (HER2-positive gastric or GEJ, KEYNOTE-811) and II/0135 (HER2-negative gastric or GEJ, KEYNOTE-859). Source
  57. US Food and Drug Administration. Supplement approval letter, Keytruda (pembrolizumab), BLA 125514/S-143, Merck Sharp & Dohme; e-signed 16 November 2023. Source
  58. Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197-2208. PubMedDOI
    CiteLoading…
  59. Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181-1195. PubMedDOI
    CiteLoading…
  60. Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133-2141. PubMedDOI
    CiteLoading…
  61. Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655-1668. PubMedDOI
    CiteLoading…
  62. European Medicines Agency. Tevimbra: EPAR, procedural steps taken and scientific information after the authorisation (archive version). Variation II/0006, extension of indication, first-line HER2-negative gastric or GEJ adenocarcinoma with PD-L1 TAP 5% or more. Source
  63. European Medicines Agency. Vyloy (zolbetuximab): European public assessment report, product page; opinion adopted 25/07/2024, marketing authorisation issued 19/09/2024. Source
  64. US Food and Drug Administration. Drug Approval Package: Tevimbra, BLA 761417, BeiGene U.S.A.; page created 29 September 2025; approval date shown on the page and on the package cover sheet: 12/26/2024 (December 26, 2024). Source
  65. US Food and Drug Administration. BLA approval letter, Vyloy (zolbetuximab-clzb), BLA 761365, Astellas Pharma US; e-signed 18 October 2024. Source
  66. Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024;42(17):2012-2020. PubMedDOI
    CiteLoading…
  67. Pan KF, Li WQ, Zhang L, Liu WD, Ma JL, Zhang Y, et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. Nat Med. 2024;30(11):3250-3260. PubMedDOI
    CiteLoading…
  68. Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876. PubMedDOI
    CiteLoading…
  69. European Medicines Agency. Enhertu: EPAR, procedural steps taken and scientific information after the authorisation (current version). Renewal EMA/R/0000282648. Source
  70. US Food and Drug Administration. Supplement approval letter, BLA 761069/S-052, IMFINZI (durvalumab) injection, AstraZeneca UK Limited; electronic signature 25 November 2025. Source
  71. US Food and Drug Administration. Corrected supplement approval / fulfilment of a postmarketing requirement letter, Keytruda (pembrolizumab), BLA 125514/S-170, Merck Sharp & Dohme; e-signed 3 April 2025; effective action date stated as 19 March 2025. Source
  72. US Food and Drug Administration. Supplement approval letter, Keytruda (pembrolizumab), BLA 125514/S-182, Merck Sharp & Dohme; e-signed 22 May 2025. Source
  73. US Food and Drug Administration. Supplement approval letter, Opdivo (nivolumab), BLA 125554/S-133, Bristol-Myers Squibb; e-signed 23 May 2025. Source
  74. US Food and Drug Administration. BLA approval letter, Tevimbra (tislelizumab-jsgr), BLA 761417, BeiGene U.S.A., Reference ID 5505117; e-signed 2 January 2025. The file name reads 'corrected'; the document itself is not labelled corrected and is the approval letter included in the Drug Approval Package. Source
  75. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med. 2025;393(3):217-230. PubMedDOI
    CiteLoading…
  76. Shitara K, Rha SY, Wyrwicz L, Oshima T, Karaseva N, Osipov M, et al. Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study. J Clin Oncol. 2025;43(29):3152-3159. PubMedDOI
    CiteLoading…
  77. Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025;393(4):336-348. PubMedDOI
    CiteLoading…
  78. Al-Batran SE, Bencivenga M, Crosby T, Dinis-Ribeiro M, Huguet F, Lordick F, et al. Gastric and oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;. PubMedDOI
  79. Casak SJ, Zhang Y, Song C, Mishra-Kalyani PS, Tang S, Auth D, et al. FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer. Clin Cancer Res. 2026;32(10):1923-1927. PubMedDOI
    CiteLoading…
  80. ClinicalTrials.gov. NCT00152217 (ACTS-GC). Registry record, accessed 20 October 2026. NCT00152217
  81. ClinicalTrials.gov. NCT04592913 (MATTERHORN). Registry record, accessed 20 October 2026. NCT04592913
  82. ClinicalTrials.gov. NCT05052801 (FORTITUDE-101). Registry record, API v2, accessed 21 October 2026. NCT05052801
  83. ClinicalTrials.gov. NCT05568095 (STAR-221). Registry record, API v2, accessed 21 October 2026. NCT05568095
  84. ClinicalTrials.gov. NCT06731478 (DESTINY-Gastric05). Registry record, API v2, accessed 21 October 2026. NCT06731478
  85. EMA. Imfinzi: EPAR - Procedural steps taken and scientific information after authorisation. PDF accessed 21 October 2026. The entry EMA/VR/0000282058 (extension of indication, combination with FLOT as neoadjuvant and adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma) shows opinion 29/01/2026 and Commission decision 12/03/2026; the column order was confirmed on the rendered page. Source
  86. US Food and Drug Administration. Supplement approval letter, Tevimbra (tislelizumab-jsgr), BLA 761232/S-018, BeOne Medicines USA; e-signed 25 August 2026. Source
  87. FDA. Withdrawn | Cancer Accelerated Approvals. Listing, content current as of 5 October 2026 (accessed 19 October 2026). Source
  88. US Food and Drug Administration. Supplement approval letter, Ziihera (zanidatamab-hrii), BLA 761416/S-002, Jazz Pharmaceuticals; e-signed 25 August 2026. Source
  89. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al. Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet. 2026;408(10560):1114-1128. PubMedDOI
    CiteLoading…
  90. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Stomach Cancer. Page accessed 21 October 2026 (raw HTML); the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Source
  91. Shah MA, Marzalik JS, Kennedy EB, Deighton D, Hamedi Z, Jhawer M, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2. J Clin Oncol. 2026;:JCO2601944. PubMedDOI
  92. Shah MA, Kennedy EB, Deighton D, Jhawer M, Kadakia KC, Mukherjee S, et al. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update. J Clin Oncol. 2026;44(12):1145-1165. PubMedDOI
  93. Shitara K, Elimova E, Liu T, Tabernero J, Lee KW, Schenker M, et al. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. N Engl J Med. 2026;394(20):2002-2014. PubMedDOI
    CiteLoading…